Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chugai Pharmaceutical, Roche's alliance partner in Japan, has said acute heart failure has been supplementally approved as an indication of Sigmart which is already available for the treatment of unstable angina pectoris.
Subscribe to our email newsletter
As a result of approving this indication, Sigmart injection is considered to offer a new therapeutic option to patients who need intravenous administration of vasodilators.
Sigmart injection is an anti-unstable anginal drug that concomitantly has a nitrate like action and ATP-sensitive potassium channel opening action.